DelMar Pharmaceuticals Inc (NASDAQ:DMPI) was up 4.5% during trading on Tuesday . The company traded as high as $0.70 and last traded at $0.69. Approximately 522,327 shares traded hands during trading, an increase of 26% from the average daily volume of 415,960 shares. The stock had previously closed at $0.66.
A number of equities research analysts have recently commented on DMPI shares. HC Wainwright set a $12.00 price target on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 23rd. ValuEngine upgraded shares of DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd.
The stock has a market cap of $15.35 million, a price-to-earnings ratio of -0.93 and a beta of 1.45.
DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings data on Tuesday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.03). research analysts forecast that DelMar Pharmaceuticals Inc will post -0.54 earnings per share for the current year.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.